

Figure S1. Melting curves of the candidate reference genes *ACTB*, *GAPDH*, *HMBS*, *PPIA* and *RPLP0*. (A) PCR amplification efficiencies of the five candidate genes. (B) Annealing temperatures and mean Cq values of the five candidate genes.




Figure S2. Characterization of serum-derived exosomes. (A) Transmission electron microscopy image showing the spherical morphology of isolated exosomes; scale bar, 100 nm. (B) Immunoblots showing EV marker expression in the isolated exosomes. Huh-7 cell lysate was used as a control. EV marker, extracellular vesicle marker; ER marker, endoplasmic reticulum marker.




Table SI. Patient clinical characteristics.

Characteristic	N=40 (%)
Age, years	56.43 (9.26)
Male sex	34 (85)
Etiology	
Hepatitis C virus infection	3 (11.11)
Cirrhosis	19 (47.5)
Differentiation	
I-II	11 (27.5)
III-IV	21 (52.5)
Platelet count, $\times 10^3/\mu\text{l}$	188.35 (79.37)
Albumin, g/dl	4.35 (0.63)
Total bilirubin, mg/dl	0.74 (0.86)
Creatinine, mg/dl	0.89 (0.18)
Aspartate transaminase, IU/l	55 (80.1)
Alanine aminotransferase, IU/l	35.3 (22.41)
AFP (>200 ng/ml)	12 (30.77)
PIVKA-II, (>40 mAU/ml)	27 (79.41)
Vascular invasion	20 (74.07)
Barcelona Clinic Liver Cancer stage	
0	7 (17.5)
A	13 (32.5)
B	3 (7.5)
C	16 (40)
D	1 (2.5)
mUICC stage	
I	7 (17.5)
II	13 (32.5)
III	13 (32.5)
IVA	4 (10)
IVB	3 (7.5)

Table SII. Log₂ fold change and P-value for expression levels of 14 reference genes selected between non-tumor group and hepatocellular carcinoma groups using the GSE114564 database.

Gene	Fold change					
	NL vs. eHCC	NL vs. avHCC	CH vs. eHCC	CH vs. avHCC	LC vs. eHCC	LC vs. avHCC
<i>ACTB</i>	1.06	1.05	1.01	1.00	1.02	1.01
<i>B2M</i>	1.18	0.68	1.12	0.65	0.98	0.57
<i>GAPDH</i>	1.15	1.09	0.90	0.85	0.79	0.75
<i>GUSB</i>	1.07	0.69	1.14	0.74	1.03	0.67
<i>HMBS</i>	1.07	1.11	0.93	0.97	0.94	0.98
<i>HPRT1</i>	0.68	0.82	0.96	1.15	1.17	1.41
<i>PGK1</i>	1.17	1.13	1.38	1.33	1.35	1.29
<i>PPIA</i>	1.15	1.14	1.08	1.08	1.03	1.02
<i>RPL13A</i>	0.72	0.73	0.64	0.65	0.62	0.63
<i>RPLPO</i>	0.89	1.02	0.93	1.07	0.89	1.03
<i>SDHA</i>	0.79	0.47	0.99	0.59	1.23	0.74
<i>TBP</i>	0.95	0.96	1.00	1.00	1.12	1.13
<i>TFRC</i>	0.99	1.06	1.56	1.67	1.69	1.80
<i>YWHAZ</i>	1.42	1.75	1.42	1.75	1.37	1.69

Gene	P-value					
	NL vs. eHCC	NL vs. avHCC	CH vs. eHCC	CH vs. avHCC	LC vs. eHCC	LC vs. avHCC
<i>ACTB</i>	0.9999	0.9999	0.9999	0.9999	0.9999	0.9999
<i>B2M</i>	0.9999	0.3582	0.9999	0.1185	0.9999	0.0067
<i>GAPDH</i>	0.9999	0.9999	0.9999	0.9999	0.4575	0.0969
<i>GUSB</i>	0.9999	0.0061	0.8168	0.1843	0.9999	0.0301
<i>HMBS</i>	0.9999	0.9999	0.9999	0.9999	0.9999	0.9999
<i>HPRT1</i>	0.0095	0.1982	0.9999	0.9999	0.9999	0.1178
<i>PGK1</i>	0.9507	0.9999	0.0004	0.0255	0.0326	0.6777
<i>PPIA</i>	0.4854	0.5129	0.9999	0.9999	0.9999	0.9999
<i>RPL13A</i>	0.0687	0.4164	0.0002	0.0008	0.0023	0.0141
<i>RPLPO</i>	0.9999	0.9999	0.9999	0.9999	0.9999	0.9999
<i>SDHA</i>	0.6492	0.0001	0.9999	0.0001	0.9999	0.2327
<i>TBP</i>	0.9999	0.9999	0.9999	0.9999	0.5414	0.1175
<i>TFRC</i>	0.9999	0.9999	0.0270	0.0005	0.0494	0.0044
<i>YWHAZ</i>	0.0051	0.0001	0.0024	0.0001	0.0610	0.0058

NL, Normal; eHCC, early hepatocellular carcinoma; avHCC, advanced hepatocellular carcinoma.